445263-82-1 Usage
Uses
Used in Medicinal Chemistry:
(6-bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine is used as a compound in medicinal chemistry for its potential to contribute to the development of new drugs. Its specific structural features may allow it to interact with biological targets, making it a candidate for further research and development in the pharmaceutical industry.
Used in Pharmaceutical Research:
In the field of pharmaceutical research, (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine is used as a compound for exploring its potential biological activities. (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine's unique structure may offer insights into novel mechanisms of action or therapeutic approaches, which could be beneficial in creating innovative treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 445263-82-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,5,2,6 and 3 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 445263-82:
(8*4)+(7*4)+(6*5)+(5*2)+(4*6)+(3*3)+(2*8)+(1*2)=151
151 % 10 = 1
So 445263-82-1 is a valid CAS Registry Number.
445263-82-1Relevant academic research and scientific papers
Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells
Bouloc, Nathalie,Large, Jonathan M.,Kosmopoulou, Magda,Sun, Chongbo,Faisal, Amir,Matteucci, Mizio,Reynisson, Jóhannes,Brown, Nathan,Atrash, Butrus,Blagg, Julian,McDonald, Edward,Linardopoulos, Spiros,Bayliss, Richard,Bavetsias, Vassilios
scheme or table, p. 5988 - 5993 (2010/11/02)
Co-crystallisation of the imidazo[1,2-a]pyrazine derivative 15 (3-chloro-N-(4-morpholinophenyl)-6-(pyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine) with Aurora-A provided an insight into the interactions of this class of compound with Aurora kinases. This led to the design and synthesis of potent Aurora-A inhibitors demonstrating up to 70-fold selectivity in cell-based Aurora kinase pharmacodynamic biomarker assays.
IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS
-
Page/Page column 45, (2010/02/10)
Compounds of Formula (I-a) and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions con
